Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

OncoSec Medical Inc. ($ONCS) announced new positive clinical data from a Phase II Investigator Sponsored Trial assessing the combination of OncoSec's investigational intratumoral therapy, ImmunoPulse® IL-12, and the approved anti-PD- 1 therapy (pembrolizumab), in patients with unresectable metastatic melanoma. The results ndicated that ImmunoPulse® IL-12 can increase response rates in patients who are not expected to respond to anti-PD-1 therapy alone.
The trial is evaluating the following key endpoints which are the best overall response rate (BORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune-related Response Criteria; safety and tolerability, duration of response. 24-week landmark progression-free survival, median PFS and overall survival.
The company stock is up over 15 percent this year so far, erasing its 12 months losses down to 18 percent.

Pernix Therapeutics Holdings Inc. ($PTX) stock price perked up as the company announced that it received a favorable opinion in its litigation with Actavis Laboratories FL, Inc. The case pertains a proposed generic version of Zohydro ER. The court concluded that Actavis’ proposed generic versions of Zohydro ER infringe U.S. Patent Nos. 9,132,096 (which expires on September 12, 2034) and 6,902,742 (set to expire on November 1, 2019) following a trial that took place in October 2016.
Both patents are listed in the FDA’s “Orange Book” for Zohydro ER and are licensed to Pernix by Recro Gainesville LLC. Pernix stock has now gained over 69 percent in this year so far while its 12 months loss stands at close to 83 percent. The stock is expected to remain solid following the new ruling.


• Aeolus Pharmaceuticals ($AOLS) announced the initiation of Phase 1 study assessing the safety, tolerability and pharmacokinetics of a single escalating dose of lead product candidate AEOL 10150 in healthy volunteers. AEOL 10150 is being developed as a treatment for the lung and delayed effects of acute radiation exposure (Lung-ARS) under a $118.4 million advanced research and development contract with the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services responsible for the development and purchase of medical countermeasures for chemical, biological, radiological and nuclear threats.
• Cellectar Biosciences ($CLRB) announced starting its fourth Cohort for Phase I clinical study of CLR 131 in patients with relapsed and refractory multiple myeloma. The cohort will consist of at least three patients with relapsed or refractory multiple myeloma that have been treated previously with at least one proteasome inhibitor and one immunomodulatory agent. The company started the cohort ahead of its guidance of initiation at the end of the second quarter of 2017. Cellectar will continues to follow all 12 evaluable patients in each of the three previously completed cohorts.

• Agenus Inc. ($AGEN) announced that its vaccine for brain tumors had failed in a mid-stage study. The revelation was made in a federal filing sating that a data and safety monitoring group had notified the company that the Phase 2 trial was likely futile. The did not provide any further details in the filing.
• Bellicum Pharmaceuticals ($BLCM) announced that it continues to receive positive data from a Phase 1 clinical trial, BP-004, assessing lead product candidate BPX-501 and rimiducid ("OFF" switch) in pediatric patients who have undergone a certain type of hematopoietic stem cell transplant. The data included incidences of GvHD- and disease-free outcomes in children with blood cancers and genetic diseases, compare favorably to historical outcomes in patients receiving a matched unrelated donor (MUD) transplant, the comparative population for our ongoing registration trial in Europe.

• Navidea Biopharmaceuticals Inc. ($NAVB) announced that it has reached a settlement with Cardinal Health Inc. This is likely to help in clearing the path to close an $80 million deal and pay off the lender next week. The company’s future is also contingent upon a firm deadline in the settlement in Franklin County Common Pleas Court. Cardinal is required to close on its purchase of North American rights to Navidea's cancer diagnostic aid Lymphoseek by March 10. Otherwise, lender CRG can foreclose on its loan by selling off shares pledged as collateral.

• MiMedx Group Inc. ($MDXG) reported its quarterly and full year results. Its full year revenue stood at $245 million, up 31% over full year 2015 revenue. It also met the company’s guidance. Net Income for the company stood at $12 million, surpassing the consensus estimates by $1 million. Its revenue for the fourth quarter was reported at $69.9 million, up 35 percent from Q4 2015 revenue. Its net income stood at $5.5 million.
• Acadia Healthcare Company Inc. ($ACHC) announced its fourth quarter adjusted EPS at $0.59. The company’s revenue for the quarter increased 41.9% to $702.9 million from $495.3 million for the fourth quarter of 2015. Its net income from continuing operations attributable to the stockholders was $41.8 million, up 21.1% from $34.5 million for the fourth quarter of 2015. Acadia’s annual revenue increased 56.6% to $2.8 billion from $1.8 billion for the year ended December 31, 2015. Net income from continuing operations attributable to the stockholders was $6.1 million, or $0.07 per diluted share, for 2016 compared with $112.4 million, or $1.64 per diluted share, for 2015.

Brokerage Action Company Rating Price Target
Cowen and Company Initiates Aerie Pharmaceuticals (AERI)
Outperform $70.00
Mizuho Upgrades Tenet Healthcare Corp (THC)
Underperform -> Neutral
Jefferies Group LLC Reiterates Healthways (TVTY)
Buy $33.00
Cantor Fitzgerald Reiterates Healthways (TVTY)
Buy $32.00

Gainers (% price change)Last TradeChangeMkt CapBioTime, Inc.BTX3.42+0.22 (6.88%)376.00MImmunoGen, Inc.IMGN2.61+0.14 (5.67%)227.86MCerus CorporationCERS4.28+0.22 (5.56%)432.70MHealthStream, Inc.HSTM24.27+1.07 (4.61%)748.39MSangamo Therapeutics IncSGMO3.85+0.15 (4.05%)254.69MLosers (% price change)ZIOPHARM Oncology Inc.ZIOP6.21-0.53 (-7.86%)812.42MClovis Oncology IncCLVS57.71-3.48 (-5.69%)2.49BInsys Therapeutics IncINSY12.80-0.68 (-5.04%)978.93MCuris, Inc.CRIS2.41-0.12 (-4.74%)322.17MInsmed IncorporatedINSM13.86-0.69 (-4.74%)834.68MMost Actives (dollar volume)Johnson & JohnsonJNJ121.70+2.18 (1.82%)330.70BPfizer Inc.PFE34.06+0.47 (1.40%)206.50BBoston Scientific Corp.BSX24.48-0.68 (-2.70%)33.18BBristol-Myers Squibb CoBMY55.77+0.42 (0.76%)94.17BEdwards Lifesciences CorpEW95.70+3.49 (3.78%)20.23B